AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02896088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: decayed tooth surfaces
Description: The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
Study NCT01521442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Yoga Therapy
Description: Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
Study NCT01521442 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control
Description: Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
Study NCT03232203 — intervention group
Intervention type: DRUG
Intervention: STRIMVELIS
Description: It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
Study NCT01989520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb formulation
Description: Single oral dose 45mg AZD5069
Study NCT01989520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Putative phase III formulation
Description: Single oral dose 45mg AZD5069
Study NCT01989520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow dissolution variant 1
Description: Single oral dose 45mg AZD5069
Study NCT01989520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow dissolution variant 2
Description: Single oral dose 45mg AZD 5069
Study NCT01989520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test treatment E
Description: Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
Study NCT01665170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Passiflora incarnata
Description: 3 x 1 tablet per day for 3 days
Study NCT01665170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 ablet per day for 3 days
Study NCT04040920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: One minute of pretreatment with ozone by using the OzoneDTA device
Study NCT04040920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pits and fissure sealants
Description: cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
Study NCT04040920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pits and fissure sealants
Description: cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
Study NCT02863302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology treatment
Description: All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
Study NCT03123822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Glasses traditionally prescribed for refractive error
Study NCT05011344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Seroneutralization and Elisa tests
Study NCT05011344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Seroneutralization and Elisa tests
Study NCT02357264 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound of the chest for the detection of fluid in the lung
Study NCT01945476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam premedication
Description: On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total.
Study NCT01945476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam premedication
Description: On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total.
Study NCT01302210 — intervention group
Intervention type: DRUG
Intervention: Decolonization
Description: 5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
Study NCT02145637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib plus Ruxolitinib combination therapy
Study NCT00462449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) through the Ness H200
Description: Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
Study NCT03078309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabis
Description: single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
Study NCT03116724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central venous catheterization through Rt. IJV
Description: * insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~* placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~* measurement of the depth of the catheter at insertion point
Study NCT03637790 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
Study NCT03637790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: rifampin
Description: In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
Study NCT00980733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified Yoghurt
Description: The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
Study NCT00980733 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yoghurt
Description: Plain yoghurt same as in intervention group without fortification
Study NCT00815503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Approved by the Danish Medicines Agency
Study NCT00815503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02644447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs Transplantation
Description: The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
Study NCT02644447 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs with Injectable Collagen Scaffold Transplantation
Description: The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
Study NCT03042910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib 1 mg orally once daily.
Study NCT01496417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
Study NCT02725437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium difficile Vaccine
Description: 0.5 mL intramuscular injection
Study NCT02725437 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL intramuscular injection
Study NCT03010241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tangbi (prescription)
Description: A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study NCT03010241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study NCT03083808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~* Docetaxel 75mg/m2 IV~* Pemetrexed 500mg/m2 IV (non-squamous only)~* Gemcitabine 1000mg/m2 IV on days 1 and 8
Study NCT03711136 — intervention group
Intervention type: PROCEDURE
Intervention: aortic prosthesis
Description: ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
Study NCT01138527 — intervention group
Intervention type: OTHER
Intervention: MRI examination
Description: 45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
Study NCT05556941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Group Intervention
Description: The investigators developed an initial Meta cognitive group intervention protocol based on the dynamic interactional model of cognition (Toglia, 2005), and specifically tailored it to individuals with schizophrenia.
Study NCT05556941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational therapy standard care
Description: Occupational therapy standard care
Study NCT04059939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading
Description: Small group reading instruction
Study NCT04059939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Management
Description: small group anxiety management skills instruction
Study NCT04059939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Business as Usual
Description: Classroom Business as Usual
Study NCT04059939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention Control (math practice)
Description: Attention Control (math practice)
Study NCT02425423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New thickened formula
Study NCT02842008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
Study NCT04472494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Specified dose on specified days
Study NCT04472494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01912053 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Therasphere® in association with Gemcitabine and Cisplatin
Description: Therasphere® is a radioelement
Study NCT03862872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-Aging Formula
Description: Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
Study NCT03862872 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Fish Oil
Description: The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
Study NCT03862872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Placebo
Description: The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
Study NCT00884845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM02734 and erlotinib
Description: PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
Study NCT00884845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
Study NCT00899977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00899977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Study NCT02524626 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study NCT02524626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation
Description: Vagus stimulation
Study NCT00953732 — intervention group
Intervention type: DRUG
Intervention: Lesion count
Description: Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Study NCT03452865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml.
Study NCT03452865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (same ml of the study drug)
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenoate Mofetil
Description: Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenoate Mofetil
Description: Mycophenoate mofetil 1 gram (g) (2\*500mg tablets or 4\*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
Study NCT02686619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
Study NCT01853189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OMT + Usual Care
Description: patients from this group received 6 sessions of OMT
Study NCT01853189 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
Study NCT03374293 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
Study NCT03374293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Antibody
Description: Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
Study NCT01544634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.